Wall Street analysts bullish on genetic testing firm Tempus AI

This was originally published on post
Seven brokerages, including J.P.Morgan, Morgan Stanley, BofA Global Research and Stifel initiated coverage with a “buy” or “overweight” rating, with the highest price target of $50 by TD Cowen. The brokerages, which were underwriters for Tempus’ initial public offering, issued their first ratings after the so-called “quiet period” ended on Tuesday. Tempus AI’s net loss widened to $289.8 million in 2023 from $214.1 million a year earlier, while total revenue jumped 65.8% to $531.8 million.